Filing Flows › Health Care › Orasure Technologies (OSUR)
Orasure Technologies (OSUR) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 7, 2026 · Orasure Technologies (OSUR) Q2 2026 earnings results →
Q2 2026 Revenue down 2% year over year to $30.6M · 20¢ of every $1 of revenue kept as net profit · operating margin 17.8%
Orasure Technologies made $30.6M in Q2 2026 (-2% Y/Y): Products and services $29.7M, Other $915K, COVID-19 $1K. Operating margin 17.8%, net earnings $6.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 7, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $30.6M in Q2 2026, down 2% year over year and up 10% from the previous quarter. HIV was the largest line at 46% of revenue. HCV lost $733K year over year (down 18%), 122% of the total change.
Gross margin was 43.5%, up 1.3 points from Q2 2025. Operating profit was $5.4M, a 17.8% margin (up 75.5 points year over year). Operating expenses fell 75% while revenue fell 2%. Net earnings were $6.2M. The effective tax rate was 0.9%.
Operating cash flow was −$9.9M. Non-cash charges added back $2.4M of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items used $20.8M. Capital expenditures of $2.4M exceeded it, leaving free cash flow of −$12.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 7, 2026 | $30.6M | -2% | 17.8% | $6.2M | −$9.9M |
| Q1 2026 | 10-Q | May 8, 2026 | $27.9M | -7% | -83.3% | −$22.4M | −$13.9M |
| Q4 2025 | 10-K | Mar 9, 2026 | $26.8M | -28% | -75.1% | −$19.3M | −$9.0M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $27.1M | -32% | -59.4% | −$13.7M | −$10.1M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $31.2M | -42% | -57.7% | −$19.7M | −$10.2M |
| Q1 2025 | 10-Q | May 7, 2025 | $29.9M | -45% | -59.3% | −$16.0M | −$19.7M |
| Q4 2024 | 10-K | Mar 7, 2025 | $37.4M | -51% | -33.2% | −$10.8M | $109K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Orasure Technologies
OTI transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. Our products and services reside under one reporting hierarchy, with commercial and innovation teams, which are part of a single business unit covering multiple product lines. Our business is principally comprised of the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions.
In its own words, from its 10-K, filed Mar 9, 2026.
Orasure Technologies against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -2% against the peers' median +5%. Operating margin: 17.8% against the peers' median 15.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OSUR Orasure Technologies | Q2 2026 | $30.6M | -2% | 17.8% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Orasure Technologies 10-Q on SEC EDGAR · CIK 1116463 · Surgical & Medical Instruments & Apparatus
13F: who owns OSUR and who is buying
More on OSUR
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results